Amgen Financial Statements From 2010 to 2025

AMGN Stock  USD 318.65  1.48  0.47%   
Amgen financial statements provide useful quarterly and yearly information to potential Amgen Inc investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Amgen financial statements helps investors assess Amgen's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Amgen's valuation are summarized below:
Gross Profit
23 B
Profit Margin
0.1224
Market Capitalization
170.4 B
Enterprise Value Revenue
6.4819
Revenue
33.4 B
We have found one hundred twenty available fundamental signals for Amgen Inc, which can be analyzed and compared to other ratios and to its rivals. Self-guided Investors are advised to validate Amgen's prevailing fundamentals against the trend between 2010 and 2025 to make sure the company can sustain itself down the road. As of the 19th of March 2025, Market Cap is likely to grow to about 133.3 B. Also, Enterprise Value is likely to grow to about 178.7 B

Amgen Total Revenue

35.1 Billion

Check Amgen financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amgen's main balance sheet or income statement drivers, such as Depreciation And Amortization of 5.9 B, Interest Expense of 3.3 B or Selling General Administrative of 2.7 B, as well as many indicators such as Price To Sales Ratio of 4.01, Dividend Yield of 0.0185 or PTB Ratio of 25.19. Amgen financial statements analysis is a perfect complement when working with Amgen Valuation or Volatility modules.
  
Check out the analysis of Amgen Correlation against competitors.

Amgen Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets96.4 B91.8 B66.8 B
Slightly volatile
Short and Long Term Debt Total63.1 B60.1 B35.6 B
Slightly volatile
Other Current Liabilities16.5 B15.7 B8.1 B
Slightly volatile
Total Current Liabilities24.3 B23.1 B11.8 B
Slightly volatile
Total Stockholder Equity5.6 B5.9 B14.3 B
Slightly volatile
Property Plant And Equipment Net3.7 B6.5 B4.9 B
Slightly volatile
Cash12.6 B12 B6.2 B
Slightly volatile
Non Current Assets Total65.9 B62.8 B37.8 B
Slightly volatile
Non Currrent Assets Other10.4 B9.9 B3.9 B
Slightly volatile
Cash And Short Term Investments10.5 B12 B18.9 B
Slightly volatile
Net Receivables7.1 B6.8 BB
Slightly volatile
Common Stock Shares Outstanding751.1 M541 M702.4 M
Slightly volatile
Liabilities And Stockholders Equity96.4 B91.8 B66.8 B
Slightly volatile
Non Current Liabilities Total66 B62.9 B40.6 B
Slightly volatile
Other Current Assets2.8 B3.3 B3.3 B
Slightly volatile
Total Liabilities90.3 B86 B52.4 B
Slightly volatile
Property Plant And Equipment Gross17.8 B16.9 B8.1 B
Slightly volatile
Total Current Assets15.6 B29 B28 B
Very volatile
Short Term Debt3.7 B3.5 BB
Slightly volatile
Inventory7.3 BB3.9 B
Slightly volatile
Accounts Payable20.5 B19.5 B3.5 B
Slightly volatile
Common Stock Total Equity27.1 B37.4 B29.3 B
Slightly volatile
Short Term Investments12.2 B12.6 B15.1 B
Slightly volatile
Capital Stock27.8 B33.5 B29.1 B
Slightly volatile
Common Stock5.6 B5.9 B26 B
Very volatile
Other Assets1.4 B2.5 B1.8 B
Pretty Stable
Long Term Debt59.4 B56.5 B33.6 B
Slightly volatile
Property Plant Equipment5.3 B6.2 BB
Slightly volatile
Good Will14.7 B18.6 B14.7 B
Slightly volatile
Intangible Assets29.1 B27.7 B15.1 B
Slightly volatile
Other Liabilities5.1 B9.1 B6.4 B
Slightly volatile
Long Term Debt Total29.9 B43 B30 B
Slightly volatile
Non Current Liabilities Other2.2 B2.3 B4.7 B
Very volatile
Long Term Investments810.9 M918.9 M714.8 M
Slightly volatile
Short and Long Term Debt3.7 B3.5 B1.8 B
Slightly volatile
Net Invested Capital54.7 B66 B54.8 B
Slightly volatile
Net Working Capital11.1 B5.9 B25.3 B
Slightly volatile

Amgen Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization5.9 B5.6 B2.4 B
Slightly volatile
Interest Expense3.3 B3.2 B1.5 B
Slightly volatile
Selling General Administrative2.7 B2.4 B4.3 B
Very volatile
Total Revenue35.1 B33.4 B22.5 B
Slightly volatile
Gross Profit21.6 B20.6 B17 B
Slightly volatile
Other Operating Expenses27.5 B26.2 B15 B
Slightly volatile
EBIT4.7 B7.8 B6.9 B
Slightly volatile
EBITDA14 B13.4 B9.3 B
Slightly volatile
Total Operating Expenses14 B13.3 B9.5 B
Slightly volatile
Income Before TaxB4.6 B6.5 B
Slightly volatile
Net Income3.2 B4.1 B5.3 B
Slightly volatile
Income Tax Expense824 M519 M1.2 B
Very volatile
Research Development3.1 BB3.9 B
Slightly volatile
Net Income Applicable To Common SharesB7.5 B5.7 B
Slightly volatile
Net Income From Continuing Ops6.3 B4.1 B5.8 B
Slightly volatile
Tax Provision493.1 M519 M1.4 B
Very volatile
Interest Income218.9 M230.4 M463.1 M
Slightly volatile
Selling And Marketing Expenses4.9 B4.7 B1.1 B
Slightly volatile
Reconciled Depreciation3.5 B5.6 B2.7 B
Slightly volatile
Non Recurring1.2 B1.4 B1.5 B
Slightly volatile

Amgen Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Begin Period Cash Flow11.5 B10.9 B5.6 B
Slightly volatile
Depreciation5.9 B5.6 B2.6 B
Slightly volatile
Capital Expenditures678.3 M1.1 B738.2 M
Slightly volatile
End Period Cash Flow12.6 B12 B6.2 B
Slightly volatile
Dividends PaidB4.8 B2.9 B
Slightly volatile
Change To Operating Activities637.1 M1.2 B692.1 M
Pretty Stable

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio4.014.21885.7732
Slightly volatile
Dividend Yield0.01850.02660.0221
Slightly volatile
PTB Ratio25.1923.993112.7531
Slightly volatile
Days Sales Outstanding46.0874.061560.6097
Slightly volatile
Book Value Per Share10.2210.863120.1736
Slightly volatile
Stock Based Compensation To Revenue0.01860.01760.0166
Slightly volatile
Capex To Depreciation0.190.1960.6657
Slightly volatile
PB Ratio25.1923.993112.7531
Slightly volatile
EV To Sales9.795.65867.0801
Pretty Stable
Inventory Turnover2.671.83743.5919
Slightly volatile
Net Income Per Share7.947.568.3771
Slightly volatile
Days Of Inventory On Hand216199257
Pretty Stable
Payables Turnover0.620.65773.6928
Slightly volatile
Sales General And Administrative To Revenue0.30.230.2781
Slightly volatile
Research And Ddevelopement To Revenue0.220.17840.1852
Slightly volatile
Capex To Revenue0.03120.03280.0705
Slightly volatile
Cash Per Share23.2422.13128.7212
Very volatile
Payout Ratio0.420.610.5007
Slightly volatile
Days Payables Outstanding583555151
Slightly volatile
Income Quality2.952.80931.7931
Slightly volatile
ROE0.730.69590.5543
Slightly volatile
PE Ratio32.7534.476267.4268
Slightly volatile
Return On Tangible Assets0.120.08990.143
Slightly volatile
Earnings Yield0.030.0290.0464
Pretty Stable
Intangibles To Total Assets0.470.50450.4306
Slightly volatile
Current Ratio1.191.25683.692
Slightly volatile
Receivables Turnover7.494.92836.2956
Slightly volatile
Graham Number26.3542.986256.1774
Very volatile
Shareholders Equity Per Share10.2210.863120.1736
Slightly volatile
Debt To Equity10.7410.22614.0757
Slightly volatile
Capex Per Share2.132.02591.2117
Slightly volatile
Revenue Per Share64.8761.781335.8187
Slightly volatile
Interest Debt Per Share12311759.4879
Slightly volatile
Debt To Assets0.690.65440.4981
Slightly volatile
Enterprise Value Over EBITDA13.4514.160924.7143
Slightly volatile
Price Earnings Ratio32.7534.476267.4268
Slightly volatile
Operating Cycle251273316
Pretty Stable
Price Book Value Ratio25.1923.993112.7531
Slightly volatile
Days Of Payables Outstanding583555151
Slightly volatile
Dividend Payout Ratio0.420.610.5007
Slightly volatile
Pretax Profit Margin0.240.13790.2899
Very volatile
Effective Tax Rate0.220.11260.1675
Very volatile
Company Equity Multiplier16.4115.62697.0802
Slightly volatile
Long Term Debt To Capitalization0.950.90590.6628
Slightly volatile
Total Debt To Capitalization0.960.91090.6744
Slightly volatile
Debt Equity Ratio10.7410.22614.0757
Slightly volatile
Quick Ratio0.910.95383.3827
Slightly volatile
Net Income Per E B T0.640.88740.8238
Pretty Stable
Cash Ratio0.490.51831.3905
Slightly volatile
Days Of Inventory Outstanding216199257
Pretty Stable
Days Of Sales Outstanding46.0874.061560.6097
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.640.90461.3554
Slightly volatile
Price To Book Ratio25.1923.993112.7531
Slightly volatile
Fixed Asset Turnover5.365.10844.2445
Slightly volatile
Enterprise Value Multiple13.4514.160924.7143
Slightly volatile
Debt Ratio0.690.65440.4981
Slightly volatile
Price Sales Ratio4.014.21885.7732
Slightly volatile
Return On Assets0.04230.04450.0787
Pretty Stable
Asset Turnover0.510.36390.3416
Slightly volatile
Net Profit Margin0.180.12240.2359
Very volatile
Gross Profit Margin0.640.61530.794
Slightly volatile
Price Fair Value25.1923.993112.7531
Slightly volatile
Return On Equity0.730.69590.5543
Slightly volatile

Amgen Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap133.3 B126.9 B118.9 B
Slightly volatile
Enterprise Value178.7 B170.2 B175.5 B
Slightly volatile

Amgen Fundamental Market Drivers

Forward Price Earnings15.1745
Cash And Short Term Investments12 B

Amgen Upcoming Events

6th of February 2024
Upcoming Quarterly Report
View
25th of April 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
6th of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Amgen Financial Statements

Amgen investors utilize fundamental indicators, such as revenue or net income, to predict how Amgen Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue-79.2 M-83.2 M
Total Revenue33.4 B35.1 B
Cost Of Revenue12.9 B13.5 B
Stock Based Compensation To Revenue 0.02  0.02 
Sales General And Administrative To Revenue 0.23  0.30 
Research And Ddevelopement To Revenue 0.18  0.22 
Capex To Revenue 0.03  0.03 
Revenue Per Share 61.78  64.87 
Ebit Per Revenue 0.22  0.26 

Pair Trading with Amgen

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Amgen position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Amgen will appreciate offsetting losses from the drop in the long position's value.

Moving together with Amgen Stock

  0.87VALN Valneva SE ADRPairCorr

Moving against Amgen Stock

  0.91ME 23Andme HoldingPairCorr
  0.89VINC Vincerx PharmaPairCorr
  0.81VERA Vera TherapeuticsPairCorr
  0.78VKTX Viking TherapeuticsPairCorr
  0.77VANI Vivani Medical Earnings Call This WeekPairCorr
The ability to find closely correlated positions to Amgen could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Amgen when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Amgen - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Amgen Inc to buy it.
The correlation of Amgen is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Amgen moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Amgen Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Amgen can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Amgen Inc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Amgen's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Amgen Inc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Amgen Inc Stock:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amgen. If investors know Amgen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amgen listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.19)
Dividend Share
9
Earnings Share
7.56
Revenue Per Share
62.242
Quarterly Revenue Growth
0.109
The market value of Amgen Inc is measured differently than its book value, which is the value of Amgen that is recorded on the company's balance sheet. Investors also form their own opinion of Amgen's value that differs from its market value or its book value, called intrinsic value, which is Amgen's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amgen's market value can be influenced by many factors that don't directly affect Amgen's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amgen's value and its price as these two are different measures arrived at by different means. Investors typically determine if Amgen is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amgen's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.